To evaluate the selectivity of the chosen compounds, we evaluated the activity of the drugs in FLT3-ITD+ AML (MV4-11 and MOLM13), FLT3-wt AML cell lines (U937 and HL60), other hematopoietic cancer cell lines, including CML (K562) and two negative control cancer cell lines, namely T-ALL (Jurkat), as well as a lung adenocarcinoma cell line (A549). The gene discussed is FLT3; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.